Global Breast Cancer Diagnostics Market Analysis & Evolving Opportunities Studied for the Period Until 2022
By test type, BRCA is expected to remain dominant in the market, with sales poised to surpass US$ 500 Mn by 2022-end. CA test for breast cancer are expected to exhibit the highest CAGR in the market through 2022, followed by ER & PR test.
View full press release